← Who reports today · Health Care
How AbbVie (ABBV) makes money: Q2 2026 revenue breakdown
US GAAP · $M · vs Q2 2025 · reported 07/31/2026
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. · Wikipedia
More about the company
AbbVie produces drugs to treat a wide range of medical issues. Market share (US pharma & biotech): ≈9% by TTM revenue.
Key growth driver: Skyrizi — the fastest-growing revenue line: $5,505, +24% y/y. · by the Q2 2026 report
How does AbbVie make money?
AbbVie brought in $17.0 billion of revenue in Q2 2026, up 10.2% year over year. The largest source was Immunology: $8.79 billion, or 52% of the total, followed by Neuroscience ($3.23B, 19%) and Oncology ($1.65B, 10%); other lines add the remaining 20%. Net income for the quarter was $3.62 billion, up 284% year over year.
Revenue by source, Q2 2026
- Immunology$8.79B · 52% · +15.1%
- Neuroscience$3.23B · 19% · +20.3%
- Other products$2.04B · 12%
- Oncology$1.65B · 10% · −1.5%
- Aesthetics (Allergan)$1.28B · 8% · +0.3%
Shares of $17.0B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
When is ABBV’s next earnings date?
Friday, October 30, 2026confirmed · before market open
AbbVie (ABBV) is scheduled to report results for the quarter ending Sep 2026 on Oct 30, 2026. Consensus EPS forecast: $3.85 (7 analysts), vs $1.86 in the same quarter last year.
Last report: Jul 31, 2026 (Q2 2026) — broken down in the Sankey chart below. Dates and consensus: Nasdaq / Zacks Investment Research; companies do reschedule. Who else reports this week →
All figures in $M.
Revenue
$16,990
+10.2%
Gross profit
$12,699
+14.6%
margin 74.7% (adj. 84.7%)
Operating income
$6,432
+31.4%
margin 37.9% (adj. 48.3%)
Net income
$3,616
+284%
EPS $2,03 · adj. EPS $3,65
Verdict: the business is healthy — +10% growth and 48% adj. operating margin; Skyrizi + Rinvoq have replaced Humira; GAAP profit is depressed by $3.2B of non-cash items
H1'26: OCF $7.3B · dividends $6.1B · buyback $1.5B · Apogee ~$10.9B · 2026 guidance: adj. EPS $13.87–14.07
Source and notation
* non-cash item. Source: AbbVie press release, 10-Q (SEC EDGAR).
Open the chart as a PNG image ↗ · for sharing and presentations · free to reuse, CC BY 4.0
ABBV earnings history: past report dates
| Jul 6, 2026 Mon | 4:12 pmafter market close | Jun 30, 2026 | $17.0B+10% y/y | $2.03+290% y/y |
| Apr 29, 2026 Wed | 7:50 ambefore market open | Mar 31, 2026 | $15.0B+12% y/y | $0.39−46% y/y |
| Jan 7, 2026 Wed | 4:08 pmafter market close | Dec 31, 2025 | $16.6B+10% y/y | $1.02 |
| Oct 31, 2025 Fri | 7:51 ambefore market open | Sep 30, 2025 | $15.8B+9% y/y | $0.10−89% y/y |
| Jul 31, 2025 Thu | 7:48 ambefore market open | Jun 30, 2025 | $15.4B+7% y/y | $0.52−32% y/y |
| Apr 25, 2025 Fri | 7:48 ambefore market open | Mar 31, 2025 | $13.3B+8% y/y | $0.72−6% y/y |
| Jan 6, 2025 Mon | 4:02 pmafter market close | Dec 31, 2024 | $15.1B+6% y/y | −$0.02 |
| Oct 30, 2024 Wed | 7:43 ambefore market open | Sep 30, 2024 | $14.5B+4% y/y | $0.88−12% y/y |
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
AbbVie: 5-year financials
| 2025 | 61,160 | 15,075 | 4,226 | 17,816 | 11,657 |
| 2024 | 56,334 | 9,137 | 4,278 | 17,832 | 11,025 |
| 2023 | 54,318 | 12,757 | 4,863 | 22,062 | 10,539 |
| 2022 | 58,054 | 18,117 | 11,836 | 24,248 | 10,043 |
| 2021 | 56,197 | 17,924 | 11,542 | 21,990 | 9,261 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP).
How we calculate
Figures are the annual report lines as filed, no adjustments. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing.
Corporate governance
2/2good
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
More
- Mar 2026Per the 2026 proxy, common stock is AbbVie's only voting security, with one vote per share. sec.gov ↗
- Dec 2025Diluted shares rose 6% over 2020–2025; SBC of $0.96B = 1.6% of $61.2B revenue (2025 10-K). data.sec.gov ↗
- Dec 2025The per-share dividend has risen every year: $4.84 (2020) → $6.65 (2025). data.sec.gov ↗
- Feb 2026The Legal Proceedings section of the 2025 10-K lists no shareholder class actions or SEC investigations — only product liability and antitrust cases. sec.gov ↗
Scoring: 2.0, no deductions: single share class, dilution +6% over 5 years (<10%), SBC 1.6% of revenue, dividend raised every year, no shareholder suits or SEC cases in the 10-K
- Share classes
- Single class: common stock is the only voting security, one share = one vote (2026 proxy).
- Dilution
- Diluted shares +6% over 2020–2025 (mostly the tail of the stock component of the 2020 Allergan deal, at market), SBC 1.6% of revenue — below thresholds.
- Disclosure
- Full US GAAP reporting: 10-K and 10-Q filed on EDGAR on time.
- Dividends
- Dividend raised every year since the 2013 spin-off ($4.84 → $6.65 over 2020–2025, XBRL).
- Lawsuits & regulators
- The 2025 10-K lists only product liability/antitrust suits (Humira, Niaspan, Allergan implants); no shareholder class actions or SEC cases.
- Related parties
- Committee approval policy for related-party transactions; no material transactions disclosed in the 2026 proxy.
How the score works · checked as of Sep 2026
AbbVie (ABBV) earnings: FAQ
How does AbbVie make money?
AbbVie brought in $17.0 billion of revenue in Q2 2026, up 10.2% year over year. The largest source was Immunology: $8.79 billion, or 52% of the total, followed by Neuroscience ($3.23B, 19%) and Oncology ($1.65B, 10%); other lines add the remaining 20%. Net income for the quarter was $3.62 billion, up 284% year over year.
When is ABBV's next earnings date?
AbbVie (ABBV) is scheduled to report on Oct 30, 2026, before market open.
When did ABBV last report earnings?
AbbVie reported Q2 2026 results on Jul 31, 2026.
What is the EPS estimate for ABBV's next earnings?
The consensus EPS forecast is $3.85 (7 analysts), vs $1.86 in the same quarter last year.
Where can I find AbbVie's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to ABBV's filings; this page breaks the latest report down in a Sankey chart.
What was ABBV's net income in Q2 2026?
AbbVie reported net income of $3,616M for Q2 2026 (+284% year over year), under US GAAP.
Does AbbVie pay dividends?
Yes. In 2025, AbbVie paid $11,657M in dividends on its common stock, per its 10-K. Earlier years are in the five-year table above.
New to earnings reports? Start with how to read an earnings report.
How this page was made: the figures come from the company's own report on SEC EDGAR; the summary and nuances were drafted by our model from that report. Figures checked against the filing. How we make the breakdowns · Report an error
More reports: ABT · Q2 2026 · AMGN · Q2 2026 · BMY · Q2 2026 · CI · Q2 2026 · CVS · Q2 2026 · DHR · Q2 2026 · ELV · Q2 2026 · GILD · Q2 2026 · HCA · Q2 2026 · ISRG · Q2 2026 · all reports